Interferon regulatory factor 2-binding protein-like (IRF2BPL) (IRF2BPL)

Interferon regulatory factor 2-binding protein-like (IRF2BPL), historically known as Enhanced at Puberty 1 (EAP1), is a multifaceted nuclear protein that functions as both a transcriptional regulator and an E3 ubiquitin ligase. It plays a pivotal role in the neuroendocrine control of puberty by facilitating the secretion of gonadotropin-releasing hormone (GnRH) and maintaining neuronal homeostasis through the regulation of the Wnt signaling pathway and the ubiquitin-proteasome system. In clinical medicine, IRF2BPL is primarily recognized for its association with NEDAMSS, a severe and progressive neurodevelopmental disorder characterized by motor regression, seizures, and loss of speech, which results from loss-of-function or dominant-negative mutations. Additionally, research has identified IRF2BPL as a co-activator of the Androgen Receptor in prostate cancer, where its elevated expression is linked to tumor progression and poor patient prognosis. While current treatments for IRF2BPL-related disorders are largely symptomatic, such as anti-seizure medications, emerging therapeutic strategies involve gene replacement therapies and investigational small molecules like CuATSM designed to restore mitochondrial function and neuronal health.

Other names

Enhanced at puberty 1EAP1C14orf4Interferon regulatory factor 2-binding protein-likeEnhanced at puberty protein 1

E3 ubiquitin ligase activity modulation, transcriptional activation of GnRH1 promoter, transcriptional repression of preproenkephalin (PENK) promoter, inhibition of Wnt signaling, and gene replacement via viral vectors.